TUSTIN, Calif., Nov. 4, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced that all six proxy resolutions passed at a special meeting of shareholders today.
The Company's proxy statement was filed with the Securities and Exchange Commission on October 14, 2011 is available at www.sec.gov and on the Company's web site: www.radient-pharma.com Radient Pharmaceuticals also announced that it has retained E & E Communications, Laguna Hills, California, and its principal, Paul Knopick, to assist with its public and investor relations program.
The following table is intended to provide the latest information on Radient's business metrics.Radient's Business MetricsCash on hand: $165,000*
*Approximate amount as of November 2, 2011Common Shares Outstanding: 647 million*
*Approximate number as of November 2, 2011.
750 million shares authorized.Outstanding Warrants & Options: 110 million*
*Approximate number as of November 2, 2011About Radient Pharmaceuticals:Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com
|SOURCE Radient Pharmaceuticals Corporation|
Copyright©2010 PR Newswire.
All rights reserved